Cargando…

Benefit of adjuvant chemoradiotherapy in patients with pathological stage III gastric cancer

BACKGROUND: For patients with locally advanced gastric cancer (LAGC) after D2 gastrectomy, the survival benefits of receiving adjuvant chemoradiotherapy versus adjuvant chemotherapy are unclear. This study aimed to compare the 5- and 7-year overall survival (OS) in the two groups and to identify whi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Gui-Fen, Zhang, Hai-Ge, Liu, Juan, Chen, Yi-Xing, Xiao, Han, Wang, Xue-Fei, He, Jian, Zeng, Zhao-Chong, Sun, Jing, Liu, Tian-Shu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612289/ https://www.ncbi.nlm.nih.gov/pubmed/31303797 http://dx.doi.org/10.2147/CMAR.S204887

Ejemplares similares

Postoperative Adjuvant Chemoradiotherapy on the Survival of Stage III Gastric Cancer
por: Li, Chao, et al.
Publicado: (2022)

Retracted: Postoperative Adjuvant Chemoradiotherapy on the Survival of Stage III Gastric Cancer
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Improving survival of stage II‐III primary gastric signet ring cell carcinoma by adjuvant chemoradiotherapy
por: Li, Yang, et al.
Publicado: (2020)

D2‐resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy
por: Peng, Jin, et al.
Publicado: (2016)

Adjuvant Chemoradiotherapy Versus Adjuvant Chemotherapy for Stage III Gastric or Gastroesophageal Junction Cancer After D2/R0 Resection
por: Shi, Jinming, et al.
Publicado: (2022)

Adjuvant therapy in patients with rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy and radical resection in pathological stages I–III
por: Lino-Silva, Leonardo S., et al.
Publicado: (2020)

Benefit of Adjuvant Chemoradiotherapy in Resected Gallbladder Carcinoma
por: Kim, Tae Hyun, et al.
Publicado: (2019)

Outcomes of “sandwich” chemoradiotherapy compared with chemotherapy alone for the adjuvant treatment of FIGO stage III endometrial cancer
por: Wang, Shao-Jing, et al.
Publicado: (2022)

Rectal cancer patients with downstaging after neoadjuvant chemoradiotherapy and radical resection do not benefit from adjuvant chemotherapy
por: Zhang, Hang, et al.
Publicado: (2020)

Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial
por: Kim, Youjin, et al.
Publicado: (2018)

DKK1 as a robust predictor for adjuvant platinum chemotherapy benefit in resectable pStage II-III gastric cancer
por: Fan, Zhiyuan, et al.
Publicado: (2022)

Definitive Chemoradiotherapy Versus Surgery Followed by Adjuvant Radiotherapy in Resectable Stage III/IV Hypopharyngeal Cancer
por: Kim, Jun Won, et al.
Publicado: (2016)

Immune Score Predicts Outcomes of Gastric Cancer Patients Treated with Adjuvant Chemoradiotherapy
por: Zou, Wei, et al.
Publicado: (2021)

Adjuvant Chemotherapy Benefit in Elderly Stage II/III Colon Cancer Patients
por: Chen, Xin, et al.
Publicado: (2022)

Prognostic significance of inflammation-based indexes in patients with stage III/IV colorectal cancer after adjuvant chemoradiotherapy
por: Yang, Jing, et al.
Publicado: (2019)

Postoperative Adjuvant Chemoradiotherapy Versus Chemotherapy Alone for Stage III Endometrial Cancer: A Multicenter Retrospective Study
por: Yoo, Ji Geun, et al.
Publicado: (2022)

Adjuvant Chemoradiotherapy for Gastric Cancer: Efficacy and Cost-Effectiveness Analysis
por: Zhang, Mengxi, et al.
Publicado: (2019)

Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II‐III gastric cancer
por: Yuan, Shu‐Qiang, et al.
Publicado: (2023)

Indirect Comparison Showed Survival Benefit from Adjuvant Chemoradiotherapy in Completely Resected Gastric Cancer with D2 Lymphadenectomy
por: Yang, Qiong, et al.
Publicado: (2013)

Pathological response to neoadjuvant therapy with chemotherapy vs chemoradiotherapy in stage III NSCLC-contribution of IASLC recommendations
por: Muñoz-Guglielmetti, Diego, et al.
Publicado: (2021)

Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: a randomized multicenter phase III trial
por: Feng, Yan-Ru, et al.
Publicado: (2016)

Adjuvant chemotherapy does not benefit patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy
por: Chen, Mingqiu, et al.
Publicado: (2018)

Impact of HER2 on prognosis and benefit from adjuvant chemotherapy in stage II/III gastric cancer patients: a multicenter observational study
por: Gao, Xianchun, et al.
Publicado: (2023)

Recurrence and survival of patients with stage III endometrial cancer after radical surgery followed by adjuvant chemo- or chemoradiotherapy: a systematic review and meta-analysis
por: Cao, Si-yu, et al.
Publicado: (2023)

The Role of Adjuvant Chemoradiotherapy Over Radiotherapy After R0 Resection for Stage II-III Esophageal Squamous Cell Carcinoma
por: Song, Tao, et al.
Publicado: (2020)

Association Between the Microsatellite Instability Status and the Efficacy of Postoperative Adjuvant Chemoradiotherapy in Patients With Gastric Cancer
por: Dai, Dongfang, et al.
Publicado: (2020)

Survival benefit of adjuvant radiotherapy in stage III and IV bladder cancer: results of 170 patients
por: Bayoumi, Yasser, et al.
Publicado: (2014)

A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma
por: Ni, Wenjie, et al.
Publicado: (2020)

Adjuvant Chemotherapy Improves Survival in Stage III Gastric Cancer after D2 Surgery
por: Chang, Shin-Chun, et al.
Publicado: (2018)

Individualized prediction of survival benefits from perioperative chemoradiotherapy for patients with resectable gastric cancer
por: Che, Keying, et al.
Publicado: (2020)

Survival benefits of perioperative chemoradiotherapy versus chemotherapy for advanced stage gastric cancer based on directed acyclic graphs
por: Zheng, Cheng, et al.
Publicado: (2023)

Elderly patients with stage II gastric cancer do not benefit from adjuvant chemotherapy
por: Guo, Jianping, et al.
Publicado: (2023)

Survival benefit after neoadjuvant or adjuvant radiotherapy for stage II–III gastroesophageal junction adenocarcinoma: A large population-based cohort study
por: Zuo, Zhichao, et al.
Publicado: (2022)

Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy for stage II nasopharyngeal carcinoma
por: Chen, Jing, et al.
Publicado: (2020)

The Efficacy of Adjuvant Chemoradiotherapy in Early-Stage Gallbladder Adenocarcinoma Depends on the Tumor Invasion Depth and Differentiation Level
por: Liang, Hui, et al.
Publicado: (2020)

Identification of Patients With Locally Advanced Gastric Cancer Who May Benefit From Adjuvant Chemoradiotherapy After D2 dissection: A Propensity Score Matching Analysis
por: Wang, Shu-Bei, et al.
Publicado: (2021)

Is it Possible to Predict Benefit from 5FU Adjuvant Therapy in Stage III Colon Cancer Patients?
por: Bonin, Serena
Publicado: (2015)

The prognostic value of lymph node ratio for local advanced gastric cancer patients with adjuvant chemoradiotherapy after D2 gastrectomy
por: Hu, Min, et al.
Publicado: (2018)

Chemoradiotherapy Is Inferior to Chemotherapy Alone in Adjuvant Setting for Signet Ring Cell Containing Gastric Cancer
por: Zhu, Yue-Ting, et al.
Publicado: (2020)

Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy
por: Wen, Bixiu, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rnsulklagehh1h9b18ndi2abss